Tag: Phase 1 trial

Microscopic illustration of T cell engaging with cancer cell through bispecific antibody mechanism
Clinical UpdatesNew StudiesPracticeResearch Digest

MAGE-A4/MAGE-A8-Targeted Bispecific T Cell Engager Shows Promise in Refractory Solid Tumors

Novel bispecific T cell engager IMA401 targeting MAGE-A4/MAGE-A8 shows encouraging safety and preliminary efficacy in phase 1a trial. Early results…

By
GMJ News Desk

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →